Serum Institute’s HPV shot gets WHO pre-qualification

1. At a Glance

• Cervavac is Serum Institute of India's (SII) recombinant quadrivalent Human Papillomavirus (qHPV) vaccine. It protects against HPV types 6, 11, 16 and 18 and has now received WHO pre-qualification (PQ) [1].
• PQ puts Cervavac on the WHO list of prequalified vaccines, so UN agencies can procure it. This moves an Indian cervical-cancer vaccine from a national product into the global public-health supply chain [1].
• The vaccine came out of a public–private–philanthropic partnership between DBT, BIRAC, WHO-IARC, the Gates Foundation and SII. That makes it a model case for "Make in India" biotech and vaccine diplomacy [1][2].
• In India, about 1.25 lakh women are diagnosed with cervical cancer every year and over 75,000 die of it. 83% of invasive cervical cancers in India are attributed to HPV 16 or 18 [2].

2. Why in the News

• October 2026: The Hindu (Chennai edition, 8 Oct 2026, p. 17) reported that Cervavac had received WHO pre-qualification [1].
• PQ makes Cervavac eligible for procurement by UN agencies [1].
• Earlier, a WHO product-choice guidance document described Cervavac as "nationally licensed" and "under review by WHO". The PQ ends that review stage [4].

3. Background & Evolution

• Rationale: India has a heavy cervical-cancer burden (1.25 lakh cases and 75,000+ deaths a year), and most of it is driven by HPV 16/18 [2]. Imported HPV vaccines were expensive, so an affordable domestic option was needed [2][8].
• Development pathway: The vaccine is an outcome of a partnership of DBT and BIRAC with the Bill & Melinda Gates Foundation, supported by SII through the "Grand Challenges India" programme [2].
• Milestones:
• September 2022: The Union Minister (Dr Jitendra Singh) announced Cervavac as India's first indigenously developed vaccine against cervical cancer [2][3].
• 2022: Indicative pricing was reported at ₹200–400 per dose [8].
• February 2024: In the Interim Budget 2024, the Finance Minister announced that the government would encourage vaccination for cervical cancer [7].
• 2025: India's HPV vaccine rollout was covered as bringing cervical-cancer prevention closer. Cervavac was priced at about ₹2,000/dose in private settings and was free or ₹0–400/dose under government programmes [6].

• October 2026: WHO pre-qualification [1].

• Related scientific base: WHO-IARC evidence summaries on protection from a single dose of HPV vaccine support simpler, cheaper schedules [5].

4. Core Static Facts

5. Multi-Dimensional Analysis

Social / Gender

• Cervical cancer kills over 75,000 Indian women a year, so an affordable vaccine is a women's-health and equity intervention [2].
• The indication covers boys as well as girls (9–26 years). This supports gender-neutral vaccination and builds herd protection [1].
• The gap between private (~₹2,000) and public (₹0–400) pricing shows why inclusion in public programmes matters for poorer households [6].

Economic

• Domestic production at a fraction of imported-vaccine prices lowers the fiscal cost of any national HPV programme [6][8].
• PQ opens UN-agency procurement markets, which raises export potential for India's vaccine industry [1].

Scientific / Technological

• The vaccine is recombinant (virus-like-particle based), with no live virus. It covers the two most oncogenic types (16/18) and two wart-causing types (6/11) [1][2].
• IARC evidence on single-dose protection could cut logistics and cost if adopted in schedules [5].

Geopolitical / Strategic

• India's role as a "pharmacy of the world" grows, and PQ supports vaccine diplomacy and Global South supply security [1].
• The project shows multilateral co-operation: WHO-IARC and Gates Foundation worked with Indian public bodies [1][2].

Governance / Administrative

• It is an example of the PPP innovation model: DBT/BIRAC funding plus private manufacturing plus philanthropic co-funding through Grand Challenges India [2].
• A national-programme rollout depends on Budget-level signalling (Interim Budget 2024) and procurement and cold-chain integration [7][6].

6. Recent Developments (last 12–18 months)

• 2025: Reporting on India's HPV vaccine rollout. Cervavac priced at ~₹2,000 in the private sector and free or ₹0–400 under government programmes [6].
• October 2026: Cervavac received WHO pre-qualification and is now eligible for UN-agency procurement [1].

7. Prelims Hooks

• Cervavac is a recombinant quadrivalent HPV vaccine made by Serum Institute of India [1].
• It targets HPV types 6, 11, 16 and 18 [1].
• Approved age group: 9 to 26 years, for both girls and boys [1].
• It is India's first indigenously developed cervical-cancer vaccine, announced in September 2022 [2].
• Announced by Dr Jitendra Singh (MoS, Science & Technology) [2].
• Developed with DBT and BIRAC support [1][2].
• International collaborators: WHO-IARC and the Gates Foundation [1].
• Partnership platform: Grand Challenges India [2].
• WHO pre-qualification allows procurement by UN agencies [1].
• 83% of invasive cervical cancers in India are attributed to HPV 16/18 [2].
• India records about 1.25 lakh new cervical-cancer cases and 75,000+ deaths a year [2].
• The Interim Budget 2024 announced encouragement of cervical-cancer vaccination [7].
• IARC has published evidence on single-dose HPV vaccine protection [5].

8. Why India's Own Free Drive Does Not Use the Indian Vaccine Yet

• The national programme started with an imported vaccine
• On 28 February 2026, the Prime Minister launched a free, nationwide HPV vaccination drive at Ajmer. It covers about 1.15 crore girls aged 14 [9][10].
• The vaccine used in this drive is Gardasil, not Cervavac [10].

• So the 'Make in India' vaccine got global approval before it got a place in India's own free programme.

• The reason is the number of doses

• WHO's expert group, SAGE (Strategic Advisory Group of Experts, which advises WHO on vaccines), now recommends one dose of HPV vaccine [11].
• Cervavac is still being tested to see whether one dose is enough. It is expected to be considered for the national programme only after 2027 [10].

• A government buying for crores of girls will prefer a vaccine already proven to work as a single dose. One dose costs less, needs fewer clinic visits and puts less load on the cold chain [5][11].

• What this means for the exam answer

• WHO pre-qualification shows the vaccine is safe and well made. It does not settle how many doses it needs.
• The single-dose trial result, not the PQ, will decide Cervavac's place in India's programme.

9. What WHO Approval Actually Opens Up, and What It Doesn't

• There is real demand: the world has been short of HPV vaccine
• WHO says global supply shortages have slowed HPV vaccine introduction since 2018. Production problems at one manufacturer made it worse [11].
• In 2023, only 27% of girls aged 9–14 worldwide had even one dose. WHO's target is 90% fully vaccinated by age 15 [11].

• Another approved low-cost supplier can help close this gap in Africa and Asia.

• But the market is already crowded

• Five HPV vaccines were already prequalified by 2024, including two from China: Cecolin and Walrinvax [11].
• Cecolin has already been confirmed by WHO for single-dose use [11]. Cervavac has not [10].

• UN buyers such as UNICEF will compare price and dose schedule. Here Cervavac starts behind a Chinese rival.

• Single dose shrinks the market for every seller

• When countries move from two doses to one, each girl needs half the vaccine.
• 57 countries used the single-dose schedule by September 2024, up from 37 in 2023 [11].
• So 'export potential' should not be measured by the old two-dose demand.

10. Why the 'Affordable Vaccine' Claim Needs a Second Look

• The promised price and the shop price are far apart
• In 2022, Cervavac was expected to cost ₹200–400 per dose [8].
• By 2025, it was about ₹2,000 per dose in private hospitals, around five times higher [6].

• Only families using government programmes got it free or at ₹0–400 [6].

• Why this matters

• The public money (DBT, BIRAC) and philanthropic money (Gates Foundation) that built the vaccine was justified by low cost [2].
• Middle-class families who go to private clinics do not see that low price.
• A fair question for Mains: when public funds help a private firm develop a product, should the price be part of the agreement?

11. What a Vaccine for 14-Year-Olds Cannot Do for Women Today

• The vaccine protects the future, not the present
• The free drive vaccinates girls at age 14 [9]. Cervical cancer usually appears decades after HPV infection.
• So the 75,000+ deaths a year [2] will not fall quickly. Women who are adults today are past the vaccination age and need screening (tests that find early changes before they become cancer).

• Vaccine news should not take attention and money away from screening.

• Boys are left out, even though the vaccine allows them

• Cervavac is approved for girls and boys aged 9–26 [1].
• The national drive covers girls aged 14 only [9][10].
• Globally, only 7% of boys are vaccinated by age 15 [11]. A girls-only programme gives less herd protection (protection that reaches people because others around them are immune).

12. What Should Happen Next

• Serum Institute and ICMR should finish and publish the single-dose trial quickly
• Cecolin's path shows how this works. Once trial data were in, WHO confirmed it for single-dose use [11].

• Without this, Cervavac stays outside both India's free programme and the cheapest UN tenders [10][11].

• The Ministry of Health should plan a switch to Cervavac once it qualifies

• The drive targets 1.15 crore girls every year [9]. Buying a domestic vaccine at the ₹200–400 level [8] instead of an imported one would cut the yearly bill and reduce dependence on one foreign supplier.

• Global shortages since 2018 [11] show the risk of relying on a single source.

• DBT and BIRAC should tie future co-funding to price commitments

• The gap between the ₹200–400 promise and the ₹2,000 private price [8][6] shows what happens without one.
• A pricing clause in Grand Challenges India–type agreements would protect the public purpose of the funding [2].

13. Anchors for Answers

• Data: Only 27% of girls aged 9–14 worldwide had one HPV dose in 2023, against a WHO target of 90% fully vaccinated by age 15 [11]
• Data: India's free HPV drive (launched 28 Feb 2026, Ajmer) targets about 1.15 crore girls aged 14 [9]
• Data: Cervavac's price: ₹200–400 per dose promised in 2022 [8], against about ₹2,000 per dose in private hospitals in 2025 [6]
• Report/Committee: WHO SAGE recommendation of a single-dose HPV schedule; IARC Evidence Summary Brief 4 on single-dose protection [11][5]
• Comparison: China's Cecolin, already WHO-confirmed for single-dose use, is ahead of Cervavac in UN tenders [11]
• Scheme: Nationwide HPV Vaccination Programme (2026), now using Gardasil; Cervavac expected to be considered after 2027 [9][10]

14. Mains Relevance

• GS-II: Issues relating to development and management of the social sector and services relating to Health. Also important international institutions (WHO).
• GS-III: Science & Technology: indigenisation of technology, developments in biotechnology; achievements of Indians in S&T.
• GS-I (secondary): Issues relating to women.
• Question stems: 1. WHO pre-qualification of an indigenous HPV vaccine marks a milestone for India's biotech ecosystem. Discuss its significance for public health in India and the Global South. (GS-III, 15 marks) 2. Cervical cancer is a largely preventable disease, yet it remains a leading cause of cancer deaths among Indian women. Examine the challenges in scaling up HPV vaccination in India. (GS-II, 15 marks) 3. Evaluate the role of public–private–philanthropic partnerships such as Grand Challenges India in driving affordable healthcare innovation. (GS-III, 10 marks)

15. Related Topics to Study Next

• WHO Global Strategy for Cervical Cancer Elimination: the global policy framework that HPV vaccination serves.
• Universal Immunisation Programme (UIP) and U-WIN: the route by which HPV vaccine would reach a national rollout.
• BIRAC and DBT innovation schemes: the funding architecture behind Cervavac.
• WHO pre-qualification vs. Emergency Use Listing (EUL): commonly confused WHO regulatory tools.
• CDSCO / DCGI and New Drugs & Clinical Trials Rules, 2019: national licensing that comes before WHO PQ.
• Gavi and UNICEF vaccine procurement: the UN-agency buyers that PQ unlocks.
• IARC: WHO's cancer agency and its single-dose HPV evidence [5].
• Other indigenous vaccines (Covaxin, ZyCoV-D, Rotavac): comparative cases of Indian vaccine innovation.

16. NCERT Concepts to Revise

• Public-private partnership (Economy): Cervavac came from DBT, BIRAC, Gates Foundation and Serum Institute working together; this explains that partnership model.
• Procurement (Economy): WHO pre-qualification matters because it lets UN agencies buy the vaccine; revise how bulk government purchasing works.
• Supply chain (Economy): Pre-qualification places an Indian vaccine in the global public-health supply chain, tied to export and distribution.
• Cold chain (Economy): Vaccine rollout depends on temperature-controlled storage and transport, which is a key challenge for national HPV programmes.
• Interim budget (Economy): The Interim Budget 2024 announced encouragement of cervical-cancer vaccination, a likely prelims fact.
• Export (Economy): Pre-qualification opens UN markets, raising India's vaccine export potential and its 'pharmacy of the world' role.

17. Common Errors / Trap Areas

• Quadrivalent ≠ bivalent ≠ nonavalent: Cervavac covers 4 types (6, 11, 16, 18). Do not confuse it with bivalent (16/18 only) or 9-valent vaccines [1][5].
• Wrong ministry: Development support came from DBT (Ministry of Science & Technology) and BIRAC, not from the Ministry of Health & Family Welfare [2].
• "Girls only" trap: Cervavac is indicated for girls and boys aged 9–26 [1].
• PQ is not market approval in India: Cervavac was already nationally licensed (2022). WHO PQ is about eligibility for UN-agency procurement [1][4].
• Partner confusion: WHO-IARC (the cancer research agency) is the collaborator, not WHO-SEARO or UNICEF. The philanthropic partner is the Gates Foundation [1][2].